What are the side effects of Ado-trastuzumab emtansine?

Ado-trastuzumab emtansine is used to treat HER2-positive breast cancer, including early-stage breast cancer and breast cancer that has spread to other parts of the body (metastatic), usually after other treatments have failed. Trastuzumab should not be used as a substitute for trastuzumab (Herceptin, trastuzumab) or for purposes not listed in this Medication Guide.

In clinical studies of trastuzumab in the treatment of metastatic breast cancer, the most common (≥25%) adverse reactions were fatigue, nausea, musculoskeletal pain, bleeding, thrombocytopenia, headache, elevated transaminases, constipation, and epistaxis. In clinical studies of trastuzumab in early-stage breast cancer, the most common adverse reactions (≥25%) were fatigue, nausea, elevated transaminases, musculoskeletal pain, bleeding, thrombocytopenia, headache, peripheral neuropathy, and arthralgia. After trastuzumab was marketed, spontaneously reported adverse reactions included tumor lysis syndrome and skin/tissue necrosis after extravasation.

EnmetratrastuzumabThe monoclonal antigenic drug has been launched in China and has entered the scope of medical insurance. Only eligible patients can be reimbursed. SpecificationsThe price of 100mg per box may be around 20,000 yuan. This drug is a strictly controlled drug. Listed overseas Enmei Trastuzumab The single-unit generic drug has Turkish and European versions, with specifications The price of each box of 100 mg may be around 3,000-8,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of the originator drugs sold domestically and abroad are basically the same, and there are currently no generic versions of Enmei Trastuzumab produced and launched.